Related Experiment Video
Updated: Jun 5, 2025
Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
New Classifications of COPD Severity Based on Impulse Oscillometry: A SAIO Grade Base on ECOPD Cohort in China
Lifei Lu1, Qi Wan1, Gaoying Tang1
1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Background:
Recently, the severities of chronic obstructive pulmonary disease (COPD) can also be assessed by impulse oscillometry (IOS). This study aimed to explore a new classification of severity of COPD based on IOS and associations with acute exacerbations (AE) in patients with COPD.
Methods:
The data of our study were based on the baseline and 2-year follow-up data of a prospective cohort in China. COPD was defined as post-bronchodilator FEV1/FVC <0.70. A new severity classification (staging of airflow obstruction by IOS, SAIO) was evaluated based on IOS parameters (R5, R5-R20, and X5 z-scores). We quantified using the weighted Bangdiwala B for agreement of severities of COPD between IOS parameters and FEV1%pred. The differences among SAIO stages were performed in symptom scores and imaging using analysis of covariance, and in the AE using Poisson regression.
Results:
Overall, 833 patients with COPD were included in this study. The weighted Bangdiwala B of R5, R5-R20, X5 z-scores, and FEV1%pred for evaluating agreement of the severities of COPD was 0.68, 0.70 and 0.83, respectively. The SAIO classifications system identified a greater number of patients with stage III-IV. SAIO provided significant discrimination between the stage I and stage III, IV for symptom scores, emphysema, and air trapping. SAIO provided significant discrimination between the stage I and other stages for AE.
Conclusions:
The SAIO classifications provide discrimination between the stage I and stage III, IV for symptom scores, emphysema, air trapping, and AE, similar to the GOLD classifications.
Trial Registration:
Chinese Clinical Trial Registry, ChiCTR1900024643. Registered on 19 July, 2019.
More Related Videos
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation